Immediate market reaction
Legend Biotech shares dropped 5.7% in pre-open trading to $20.95 after the company announced that founder and long-time chief executive Ying Huang has stepped down. The board named Alan Bash, who currently serves as President of the CARVYKTI Business Unit, as Interim CEO while it conducts a search for a permanent successor.
Leadership transitions of this kind often introduce near-term uncertainty, particularly for a clinical-stage biotechnology company where an outgoing CEO has guided strategy for seven years.
Analyst moves and commercial concerns
The stock’s decline also follows recent analyst activity. UBS lowered its rating from Buy to Neutral roughly three days ago and cut its price target to $28. In its note, UBS expressed concern that Gilead’s anito-cel - expected to launch in late 2026 or 2027 - could win meaningful share in multiple myeloma and weigh on Carvykti’s growth. UBS additionally pointed out that sequential quarterly worldwide sales growth for Carvykti has been running at the lower end relative to prior years and warned that increasing competitive crowding could exacerbate this trend.
RBC Capital held its Outperform rating but reduced its price target to $59 from $63, signaling a more cautious short-term view despite keeping a favorable long-term stance.
Company-specific dynamics versus market backdrop
The broader indices offered little support for Legend’s shares. The S&P 500 was higher by 0.8%, the Nasdaq advanced 1.2%, and the Dow Jones gained 1.2%, meaning Legend’s stock materially underperformed during a risk-on session. That divergence suggests the move was driven predominantly by company-specific developments rather than macroeconomic factors.
Together, the CEO departure and the continued selling pressure since the UBS downgrade have created a compounded negative narrative around Legend’s near-term outlook. Investors appear reluctant to accept additional uncertainty without more clarity on the company’s leadership path and on Carvykti’s competitive positioning in multiple myeloma.
Valuation context
The stock is trading substantially below its 52-week high of $43.71 and is nearer to its 52-week low of $16.24, reflecting the market’s reassessment of the company amid the twin forces of management turnover and analyst caution.
For now, the combination of a founder-led CEO exit, an interim executive at the helm, and recent analyst downgrades have created a climate of heightened uncertainty for Legend Biotech and its shareholders.